Amgen says Lumakras 加える immunotherapy for 肺 癌 needs その上の 熟考する／考慮する
By Deena Beasley
Aug 7 (Reuters) - A small 熟考する／考慮する of Amgen Inc's Lumakras 麻薬 連合させるd with immunotherapy 設立する it helped 29% of 前進するd 肺 癌 患者s, but 肝臓 有毒性 was high and その上の 熟考する／考慮する is needed, the company said ahead of the data 贈呈 on Sunday at the World 会議／協議会 on 肺 癌 in Vienna.
Nearly all of the 58 裁判，公判 患者s 扱う／治療するd with the highest dose of genetic-突然変異 的ing Lumakras experienced elevated 肝臓 enzyme levels, and about 20% given the lowest dose saw 重要な 肝臓 有毒性, 研究員s said.
The findings are the first 指示，表示する物 of how 井戸／弁護士席 Lumakras 作品 in combination with 麻薬s that help the 免疫の system attack 癌 - Merck & Co's Keytruda and Roche 持つ／拘留するing AG's Tecentriq.
Lumakras is an oral 麻薬 designed to 的 a 突然変異するd form of a 遺伝子 known as KRAS that occurs in about 13% of 非，不，無-small 独房 肺 癌s, the most ありふれた form of the 病気, and いっそう少なく frequently in some other solid tumors.
It was 認可するd by the U.S. Food and 麻薬 行政 last year for 前進するd 肺 癌 患者s with KRAS 突然変異s whose 病気 has より悪くするd after 治療 with chemotherapy or other 薬／医学s, but Amgen is 実験（する）ing whether the 麻薬 could be used as an earlier 治療.
The 熟考する／考慮する 設立する that 17 out of 58 患者s with 前進するd NSCLC - most of whom were 以前 扱う／治療するd with immunotherapies - had tumor shrinkage. の中で the 17 responders, the median duration of 返答 was 17.9 months.
"It is not a 激突する-dunk success with the combination as we had hoped for ... 明確に high doses were not tolerable," Dr. （頭が）ひょいと動く Li, an oncologist at 記念の Sloan Kettering 癌 中心 and the 熟考する／考慮する's lead 捜査官／調査官, told Reuters. "There still s eems to be a path 今後."
Amgen said the next iteration of the 熟考する／考慮する will 入会させる only 患者s not 以前 扱う／治療するd with an immunotherapy. To 限界 the 危険 of 肝臓 有毒性, it will use a low dose of Lumakras as a lead-in, followed by the combination of Lumakras and Keytruda. Tecentriq will no longer be part of the 裁判，公判.
"I 嫌疑者，容疑者／疑う we will have data some time next year," said David Reese, Amgen's 研究 and 開発 長，指導者.
Amgen said it is also starting a 熟考する／考慮する of Lumakras in combination with chemotherapy as an 初期の 治療 for 前進するd NSCLC 患者s who 実験（する） 消極的な for PD-L1, a protein 的d by 麻薬s like Keytruda that helps 癌 独房s hide from the 団体／死体's 免疫の system. (報告（する）／憶測ing By Deena Beasley; Editing by Jan Harvey)
